Summary XR9051 (N-(4-(2-(6,7-Dimethoxy-1 .2,3,4,-tetrahydro-2-isoquinolyl)ethyl)phenyl)-3-((3Z,6Z)-6-benzylidene-1 -methyl-2.5-dioxo-3-piperazinylidene) methylbenzamide) was identified as a potent modulator of P-gtycoprotein-mediated multidrug resistance (MDR) following a synthetic chemistry programme based on a natural product lead compound. The Correspondence to: P Chartton has been well documented. but at present its role in solid tumours is less clear.
[3H]daunorubicin from preloaded cells and, unlike CsA and Vpm, remained active for several hours after removal of resistance-modifying agent. In photoaffinity labelling experiments employing [3H]azidopine, XR9051 was able to displace binding to P-glycoprotein. In binding studies using [3H] vinblastine, XR9051 was shown to be a potent inhibitor of the binding of the cytotoxic to P-glycoprotein (ECO= 1.4 ± 0.5 nM). Taken together.
the results indicate that XR9051 reverses the MDR phenotype through direct interaction with P-glycoprotein.
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The treatment of cancer w ith chemotherapeutic drugs is frequently impaired or ineffectixe as a result of intrinsic or acquired resistance of the tumour cells. Many types of cancer. such as solid tumours of the colon and lix-er. appear innatelv refractorv to the cvtotoxic influence of anti-cancer drucs. wNhereas others. such as breast and oxarian cancers. often respond w-ell initially but subsequently relapse. Multidrug resistance (MDR) is the phenomenon in which exposure of tumour cells to a single cytotoxic agent results in cross-resistance to other structurallx unrelated classes of cxtotoxics (Gottesman and Pastan. 1993) . This familx of 'MDR cytotoxics includes drugs of clinical importance such as the anthracvclines. X inca alkaloids and paclitaxel ( Gottesman and Pastan 1993) .
Althouah there are sex eral different mechanisms bx w hich resistance can emerge ( Simon and Schindler. 1994) by far the most extensixvelv characterized is P-gly coprotein-mediated MDR. Pglxcoprotein (P-gp) is a plasma membrane protein of 170 kDa that is encoded bv the MDR] gene and acts as an energNx-dependent drug efflux pump. preventing the accumulation of drugs by expelling them from the cell membrane before they are able to interact w-ith their cellular target (Gottesman and Pastan. 1993) . The clinical sianificance of P-ggp in haematological malignancies has been well documented. but at present its role in solid tumours is less clear.
A broad range of compounds has been identified that are able to rexverse the MDR phenotype by interacting with P-gp and blocking the efflux of cvtotoxics from cells. These compounds include peptides. steroids. calcium channel blockers. cardiox ascular drugys and immunosuppressix e and antifungal agents (reviewed by Ford. 1996) . Their use has been limited bx the inabilitN to achiexe clinically effectixe plasma or tumour concentrations to inhibit P-gp function before non-specific. deleterious toxicities are encountered (Lum et al. 1993: Raderer and Scheithaeur. 1993) . The requirement for more selectixe and potent agents as resistance modifiers has led to the identification of a number of secondgeneration modulators. such as a non-immunosuppressix e cxclosporin derivatixe SDZ PSC 833 (Boesch et al. 1991) . an acridonecarboxamide derixatixe. GG918 (Hvafil et al. 1993) . and a triazinoaminopiperidine derixitixe. S9788 (Pierre et al. 19921 . These compounds are currentlx in clinical trial. The demonstration that potent modulators can oxercome resistance in P-gp-oxerexpressing cell lines and tumours is a vital step in answerinc the question of whether inhibition of P-gp function w ill be an effectix e therapeutic strategy.
XR9051 (Figure 1 ) xas identified from a medicinal chemistrx programme based on a diketopiperazine originally isolated from the fermentation of a Streptomyces species. In this paper. we descnrbe the in X itro profile of XR905 1. wxhich illustrates its promise as a nexx drug for the treatment of MDR tumours. 
MATERIALS AND METHODS Cell lines
Parental EMT6 mouse mammary carcinoma (EMT6/P) and H69/P small-cell lung carcinoma cell lines and their corresponding drug-resistant sublines EMT6/AR 1.0 (Twentyman et al. 1990) and H69/LX4 (Twentyman et al. 1986) were from stocks held by the MRC Clinical Oncology and Therapeutics Unit. Cambridge. UK. Parental A2780 human ovarian carcinoma cells and their drugresistant counterparts 2780AD (Rogan et al. 1984) were provided by Dr T Hamilton (Fox Chase Cancer Center. Philadelphia. PA. USA).
Parental murine P388 leukaemia (P388/P) and drug-resistant P388/DX Johnson cell lines (Johnson et al. 1978) were kindly provided by Dr M Grandi (Pharmacia Upjohn. Milan, Italy).
The MC26 murine colon carcinoma cell line, which is intrinsically drug resistant. at least in part as a result of P-gp expression. was provided by Dr SA Watson (University Hospital. Nottinghamn UK).
All cell lines were maintained in RPMI-1640 medium (Gibco) supplemented with L-glutamine (2 mm) and 10% fetal calf serum at 37°C in a humidified atmosphere of 95% air and 5% carbon dioxide. P388/P and P388/DX Johnson cultures were additionally supplemented with 6 miM 2-mercaptoethanol. All drug-resistant lines, with the exception of CHrB30 cells, were maintained under positive selection pressure by treatment with doxorubicin for one passage every 3-4 weeks. These doxorubicin-treated cultures were subsequently incubated in drug-free medium for one passage before experimental use. The drug-resistant Chinese hamster ovary cell line CHrB30 was grown in a-MEM supplemented with nucleosides and 30 jg ml-' colchicine to maintain resistance as described previously (Kartner et al, 1983) . The same medium but lacking colchicine was used to culture the parental AuxB 1 cell line. After a further 1-h incubation. cytotoxics were added at fourfold concentration in a volume of 50 gl. Plates were then incubated for 4 days (EMT61P. EMT6/AR 1.0 and MC26) or 5-6 days (A2780. 2780AD) before cell proliferation was assessed using the sulphorhdiamine B (SRB) assay as described previously (Skehan et al. 1990 ).
Drugs
For suspension cultures cellular proliferation was quantified after the appropriate incubation period (5-6 days for H69/P: H69/LX4; 4 days for P388/P:P388/DX Johnson) using the redox reagent AlamarBlue (Serotec. UK Hyafil et al (1993) . Briefly. cells were seeded at a density of 4.8 x 10 per well in 24-well plates (Falcon). After allowing cells to proliferate for 48 h. culture medium was removed and replaced with 0.5 ml of loading medium (glucose-free culture medium supplemented with 10 mm sodium azide. 50 nm. Hepes. pH 7.4. 2 jm daunorubicin including 0.3 jCi ml-' [H]daunorubicin and resistance-modifying agents, as appropriate). Plates were incubated at 37°C for 2 h before washing wells rapidly twice with growth medium and replacing with .efflux medium' (culture medium supplemented with 50 mM Hepes, pH 7.4, with or without resistance-modifying agent) and further incubation at 37°C. At varying time points during the efflux phase, wells were washed rapidly four times using ice-cold PBS and left to dry. At the end of the assay. cells were solubilized in 500 jil 0.1 N sodium hydroxide and transferred to scintillation vials containing 4.5 ml of scintillation fluid. Cell-associated radioactivity was measured using a Canberra Packard TriCarb 2000 scintillation counter. and three-to fivefold less potent than XR905 I respectively (Table   Results are plotted relative to 100 pM Vpm, which restores uptake to levels 1). It is also noteworthy that the higher but submaximal concentraseen with parental EMT6/P cells. The results shown are representative of at tions of both Vpm and CsA had inherent cytoxicity in two of four least six independent experiments. Mean ± standard deviation (n = 4) cell lines in the absence of doxorubicin. No such inherent toxicity was observed for XR905 1.
In the parental line, EMT6/P, a weak sensitizing influence of and methotrexate. XR9051 (0.3 JM) gave significant reversal of studies (Hyafil et al, 1993; Dantzig et al, 1996) .
( Table 2 ). Only the activity of agents associated with the MDR phenotype was sensitized by XR905 1. Thus, the modulator had no Accumulation of [3H]daunorubicin influence on the activity of the non-MDR cytotoxics, 5-fluorouracil The ability of resistance-modifying agents such as XR9051I to reverse the drug accumulation deficit in P-gp-expressing cell lines has been widely used to demonstrate inhibition of P-gp-dependent aPotentiation index is defined as (IC50 of the cytotoxic in the absence of
The ability of resistance-modifying agents to inhibit the efflux of modulator/IC,n of the cytotoxic in the presence of modulator).
[3H]daunorubicin from EMT6/AR 1.0 cells was investigated using
British Journal of Cancer (1998) 78(7) after removal of XR9051 from medium. Cells were exposed to XR9051, Vpm by P-glycoprotein (Boesch and Loor, 1994; Spoelstra et al, 1994) . The experiment shown in Figure 4 was designed to complement accumulation assay. Data points represent the mean (±s.d., n = 4), and the data from the previous section that indicates that XR905 1 has a graph shown is representative of four independent experiments long duration of action. Cells were exposed to modulator for 1 h before thorough washing and a further incubation in the absence of modulator for up to 22 h before assessing the cells ability to accua 'loading phase' of 2 h in the presence of [3H]daunorubicin and mulate [3H]daunorubicin. The results indicate that cells exposed to modulator, followed by an 'efflux phase' (after washing) in which 1 ,tM XR9051 for 1 h showed complete reversal of the P-gpcells were incubated either in daunorubicin and modulator-free dependent accumulation deficit for at least 22 h. The last time medium or in medium containing modulator only. Resistance point (22 h) showed higher accumulation than the earlier time modulators were used at a concentration sufficient for maximal points because of cell division taking place during the incubation reversal of the accumulation deficit (1 ,tM for both CsA and period. The prolonged activity of XR9051 was in sharp contrast to
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British Journal of Cancer (1998) 78 (7) (Figure 2 ). These results demonstrate that, in contrast to CsA and Vpm, XR905 1 has a very long duration of action after removal from the incubation medium.
Inhibition of photoaffinity labelling of P-gp by XR9051
The dihydropyridine azidopine has been widely employed as a photoaffinity ligand, for both calcium channels and P-gp (Ferry et al. 1984 : Yang et al. 1988 . It is possible to evaluate the ability of resistance-modifying agents to interact directly with P-gp by examining their inhibition of [3H]azidopine cross-linking to the 170-kDa P-gp band on polyacrylamide gels. Photoaffinity labelling of cell membranes prepared from H69/LX4 cells confirmed the presence of a 170-kDa band that was not present in membranes prepared from the parental H69/P cell line ( Figure 5 ).
This reflects the pattern of P-gp expression in these cell lines, which was confirmed by Western blot analysis using the anti-P-gp antibody C219 (data not shown). As shown in Figure 5 , XR9051
(1-20 jM) was able to inhibit the labelling of P-gp by (Callaghan et al. 1997 Figure 6 , and data obtained using XR9051, Vpm and CsA are summarized in Table 3 
DISCUSSION
This current study was undertaken to characterize a specific inhibitor of P-gp that is more potent and lacks the side-effects of some of the modulators currently undergoing clinical assessment in refractory cancers. Extensive modification of a natural product lead resulted in XR905 1. which was found to be active at submicromolar concentrations in a number of assays assessing P-gp-dependent MDR.
Several assays were used to examine the inhibition of P-gp transport and the direct interaction between XR905 1 and its target. Drug accumulation assays were used to demonstrate that XR905 1 reversed the accumulation deficit associated with overexpression of P-gp. In the murine EMT6/AR 1.0 mammary carcinoma cell line, XR9051 was more potent than both CsA and Vpm in restoring [3Hldaunorubicin accumulation. XR9051 also proved highly potent in reversing the accumulation deficit of the fluorescent probes calcein-AM and rhodamine-123 in human and murine cell lines (data not shown). In contrast to the resistant cell lines, XR9051 had little effect on drug accumulation in parental cell lines, indicating that it exerted its influence through inhibition of P-gp function. Furthermore, XR9051 showed no activity in a cell line whose resistance to cytotoxic drugs is mediated by the multidrug resistance-associated protein, MRP (data not shown). Thus, XR905 1 appears to be a specific inhibitor of P-gp-mediated transport. Evidence for a direct interaction between XR905 1 and P-gp was implied by the photoaffmnity labelling studies using the photoreactive P-gp substrate azidopine. XR9051 appeared to be less potent than CsA in this assay, which suggests that the two modulators may not interact with P-gp at exactly the same site. This interaction was confirmed by the ability of XR9051 to displace the binding of [3H]vinblastine to P-gp. In this assay XR9051 was significantly more potent than CsA and Vpm.
Nevertheless. XR905 1 was not able to completely displace [3H]vinblastine binding. possibly due to an interaction at a region distinct from the vinblastine binding site as has been proposed for 1.4-dihydropyridines (Ferry et al, 1992) . Such a mechanism of action for XR9051 may explain the discrepancy between the concentrations needed to displace [3H]vinblastine and those needed to reverse MDR in cell-based assays. Confirmation of this hypothesis awaits kinetic studies on drug binding.
The characterization of XR9051 was extended to assess the reversal of the MDR phenotype in a number of cell lines. where the restoration of cytotoxic drug accumulation in MDR cell lines was found to correlate with the restoration of cytotoxic-mediated cell kill. XR905 1 was found to be effective in potentiating the toxicity of several clinically relevant MDR drugs in a range of murine and human P-gp-overexpressing MDR cell lines. The cell lines examined included those of leukaemic origin as well as cell lines derived from solid tumours such as breast. ovary and lung. A concentration of 0.3-0.5 gM was sufficient for full reversal of resistance. In most cases significant potentiation of activity was seen at concentrations of 0.1 JIm. indicating that XR905 1 is one of the more potent modulators known. An important property of an effective MDR modulator is that its activity persists in vitro for an extended period following removal from the culture medium. This feature should give the modulator a significant advantage for clinical administration. Two different transport studies demonstrated that XR905 1 was particularly effective in inhibiting P-gp function for in excess of 22 h. even after removal from culture medium. This is in marked contrast to both CsA and Vpm. which are both known as P-gp substrates. This difference in properties may suggest that XR905 1 is not a substrate for export by P-gp and may give further evidence that XR9051 binds to a distinct but linked site to that of cytotoxics and other P-gp substrates. Nevertheless, it should be noted that the ability of a P-gp inhibitor to retain activity over an extended period may affect the tissue distribution and pharmacokinetics of other compounds. Studies in mdrla (-I-) knockout mice have suggested that P-gp can influence the pharmacology of drugs other than anti-cancer agents. especially in the blood-brain barrier (Schinkel et al. 1995) .
In summary, XR905 1 has been demonstrated to be a potent and specific inhibitor of P-gp function in vitro. with a superior duration of action to other agents tested. The compound is significanfly more potent than CsA and Vpm. Furthermore. on the basis of published data. XR9051 is more potent than S9788 (Pierre et al. 1992 ) and VX71O (Germann et al. 1997) . XR9051 is effective in restoring the sensitivity of many different tumour types to numerous MDR chemotherapeutic agents and therefore has great potential in the treatment of refractory cancers.
